Showing results (91-100 of 830) with videos related to

Sort By:
Pageof 83
Pharmacogenetics|March 27, 2001
Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibilityH Wikman, S Thiel, B Jäger, et al.
Pharmacogenetics|March 30, 2000
Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosisM Wadelius, E Stjernberg, B E Wiholm, et al.
Pharmacogenetics|March 30, 2000
Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's diseaseA J Makoff, J M Graham, M J Arranz, et al.
Pharmacogenetics|March 30, 2000
Discovery of a functional polymorphism in human glutathione transferase zeta by expressed sequence tag database analysisA C Blackburn, H F Tzeng, M W Anders, et al.
Pharmacogenetics|March 30, 2000
Characterization of human polymorphic DNA repair methyltransferaseR Inoue, M Abe, Y Nakabeppu, et al.
Pharmacogenetics|April 13, 2000
CYP1A1 polymorphisms and lung cancer risk: a meta-analysisR S Houlston
Pharmacogenetics|April 13, 2000
Refining the mouse chromosomal location of Cdm, the major gene associated with susceptibility to cadmium-induced testicular necrosisT P Dalton, M L Miller, X Wu, et al.
Pharmacogenetics|April 13, 2000
Influence of genetic polymorphisms in the beta2-adrenoceptor on desensitization in human lung mast cellsL K Chong, J Chowdry, P Ghahramani, et al.
Pharmacogenetics|April 13, 2000
Association between functional genetic polymorphisms of human sulfotransferases 1A1 and 1A2C E Engelke, W Meinl, H Boeing, et al.
Pharmacogenetics|October 19, 2000
Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trialM P Murphy, M E Beaman, L S Clark, et al.
Pageof 83